Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationThe clinical utility of aflibercept for diabetic macular edemaThe role of aflibercept in the management of diabetic macular edemaNanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug deliveryNovel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of LiteratureThe Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsVascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Current intravitreal pharmacologic therapies for diabetic macular edema.Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration.Molecular pathogenesis of retinal and choroidal vascular diseases.Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD.Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical AdministrationVEGF regulates local inhibitory complement proteins in the eye and kidney.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs.Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic AtrophyThe remote effects of intravitreal anti-VEGF therapy.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye.Fellow eye effect of unilateral intravitreal anti-VEGF injections in eyes with diabetic macular edema.Ten years of anti-vascular endothelial growth factor therapy.One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion.Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.Clinical pharmacology of intravitreal anti-VEGF drugs.
P2860
Q24193614-3B4543B3-F89D-4417-9D36-61C6C85AA384Q26771522-59667D5D-256A-418C-8C74-AC5EB03D33D5Q26783575-62B25708-6119-4391-B56A-7CDCC8A52DE0Q26798348-D813FFC2-03AC-4A8E-A3D1-E59D9EFE3628Q27007119-DB068D44-5AD7-4327-A40D-B91BD61D00F9Q28066675-4E9393FF-268C-45BA-AAA2-06864277B9D1Q28081000-066832AD-A94A-46FE-B13F-9DAC27000C73Q28550616-B30F7E3F-36D9-45DE-9C88-805F7742F23FQ30244247-AB18E25E-7165-44CE-A585-24073828FE9FQ30490738-BA07FD26-EF4B-43C5-B1E1-C5D5E3698CD9Q33740152-3327E60F-97C2-41B2-8456-970032E17F4BQ33790460-9957EFD6-C720-4FBF-90E2-DD73D1C721C4Q35016867-48279E2C-58F0-4DEA-8A66-17C595CDCC98Q35650268-88ACD754-83AA-4125-BD1D-B3FC0342AE1AQ35884984-9F9121EB-BA9A-4110-AB1F-9F5CECD7E67CQ36013973-0E469A69-5B80-4F19-B0F1-7BE123BDD0A9Q36039050-E5F84385-9BC1-4D61-989F-75A18C2E315CQ36200924-75177B34-1EA5-4229-8C49-E862F93E00ACQ36209048-2E97CFBD-84D4-4378-AEB3-3BC0FDE477FBQ36287622-5D665E22-A928-4B87-B251-80D700A43C8BQ36296789-A1ACAFA3-087C-4320-BDF1-F2895DDBD94AQ36338786-A00E9141-1FE7-4C68-90F1-F89582F146B6Q36583714-A5C1DCDC-B941-4A6B-AE3D-3C5E097A3BEBQ36757415-2201625F-DAC4-401C-AAAF-073B8756517FQ36881990-EA837609-2A08-4E6B-ABDD-C7507D7EB5C4Q37545004-828D064C-9AE1-4369-936D-4851990B0CDBQ38528148-DAA6E137-6384-46E9-BB4E-2C654C982A75Q38897856-0331FDD2-C5A5-438B-9274-AD35C474EF07Q40358167-293CAF5A-3272-4873-AB9E-22DFE3FC5301Q40426766-2DD34EC9-68DA-4450-905B-1AE75C399D9FQ40990867-962EC9FA-FFB5-4E25-B4C6-605D359A6EDEQ41222963-FE2B684F-7BD7-4DD0-964A-2B4206FD56CDQ43149049-2E28308C-B7F6-431A-A9A2-AD35D3EBF761Q46407140-99C5696C-08D7-48EE-8C60-69ADD74CAAF8Q47162242-7912AFF4-CB62-46AA-962F-2256B84C0812Q47198245-6180E4D1-D35D-4020-BDE8-5B04EA15B8F9Q47229423-3C72B4F7-A441-4C8E-9B71-27429502AE3FQ47405816-3C461739-3B33-46AD-A6E8-B09632DE525DQ47761710-960EA6EA-33A6-47C8-A933-D6580E00FD8AQ48109878-E2CA09A3-ED83-422B-9A10-5BA28E387714
P2860
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@ast
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@en
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@nl
type
label
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@ast
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@en
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@nl
prefLabel
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@ast
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@en
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@nl
P2093
P2860
P1476
Systemic pharmacokinetics foll ...... patients with neovascular AMD
@en
P2093
Alessandro A Castellarin
Dante Joseph Pieramici
Dilsher S Dhoot
Jennifer E Visich
Ma'an A Nasir
Melvin D Rabena
Nathan C Steinle
Robert L Avery
Robert See
P2860
P304
P356
10.1136/BJOPHTHALMOL-2014-305252
P407
P577
2014-07-07T00:00:00Z